+40.6%
NVDL vs MRNA
+511.3%
-470.7%
-42.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | -2.2% | +3.9% | +1.6% |
| 7D | +11.7% | +5.5% | +6.2% | +11.7% |
| 30D | +7.8% | +158.7% | -150.9% | +6.9% |
| 3M | +3.3% | +182.1% | -178.8% | -0.9% |
| 6M | +38.9% | +151.8% | -112.9% | +33.4% |
| YTD | +28.5% | +393.6% | -365.1% | +24.1% |
| 1Y | +40.6% | +499.5% | -458.9% | +38.1% |
| All | +40.6% | +511.3% | -470.7% | +38.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling